Analyst Scoreboard: 5 Ratings For Insulet

Insulet PODD has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Insulet, presenting an average target of $227.0, a high estimate of $238.00, and a low estimate of $208.00. This current average reflects an increase of 17.25% from the previous average price target of $193.60.

Breaking Down Analyst Ratings: A Detailed Examination

In examining recent analyst actions, we gain insights into how financial experts perceive Insulet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Insulet. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insulet compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for Insulet's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

To gain a panoramic view of Insulet's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Insulet analyst ratings.

Delving into Insulet's Background

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.

Financial Milestones: Insulet's Journey

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Over the 3 months period, Insulet showcased positive performance, achieving a revenue growth rate of 26.97% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Insulet's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.99% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Insulet's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.94%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Insulet's ROA stands out, surpassing industry averages. With an impressive ROA of 2.14%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Insulet's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.34, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

The Significance of Analyst Ratings Explained

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.